- Home
- NRIM vs BNTC Comparison
NRIM vs BNTC Comparison
Compare NRIM & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- BNTC
- Stock Information
- Founded
- NRIM 1990
- BNTC 1995
- Country
- NRIM United States
- BNTC United States
- Employees
- NRIM N/A
- BNTC N/A
- Industry
- NRIM Savings Institutions
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- NRIM Finance
- BNTC Health Care
- Exchange
- NRIM Nasdaq
- BNTC Nasdaq
- Market Cap
- NRIM 444.5M
- BNTC 365.1M
- IPO Year
- NRIM N/A
- BNTC N/A
- Fundamental
- Price
- NRIM $22.22
- BNTC $16.17
- Analyst Decision
- NRIM
- BNTC Strong Buy
- Analyst Count
- NRIM 0
- BNTC 5
- Target Price
- NRIM N/A
- BNTC $24.80
- AVG Volume (30 Days)
- NRIM 108.3K
- BNTC 66.2K
- Earning Date
- NRIM 10-22-2025
- BNTC 11-13-2025
- Dividend Yield
- NRIM 2.88%
- BNTC N/A
- EPS Growth
- NRIM 91.41
- BNTC N/A
- EPS
- NRIM 2.80
- BNTC N/A
- Revenue
- NRIM $201,544,000.00
- BNTC N/A
- Revenue This Year
- NRIM $11.35
- BNTC N/A
- Revenue Next Year
- NRIM $7.32
- BNTC N/A
- P/E Ratio
- NRIM $7.92
- BNTC N/A
- Revenue Growth
- NRIM 42.34
- BNTC N/A
- 52 Week Low
- NRIM $15.92
- BNTC $9.10
- 52 Week High
- NRIM $25.05
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- NRIM 25.56
- BNTC 62.96
- Support Level
- NRIM $20.70
- BNTC $15.20
- Resistance Level
- NRIM $21.60
- BNTC $16.76
- Average True Range (ATR)
- NRIM 0.76
- BNTC 0.91
- MACD
- NRIM 2.54
- BNTC 0.04
- Stochastic Oscillator
- NRIM 74.54
- BNTC 77.90
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.